DCGI nod to phase-I clinical trial of COVID-19 vaccine of Reliance Life Sciences

By: |
September 03, 2021 10:20 PM

The firm is required to submit the revised clinical trial protocol for immunogenicity to be assessed on Day 42, instead of Day 14, as recommended by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation, a source said, citing the conditions set for the trial.

One vaccine candidate has been developed from the plant virus named cowpea mosaic virus while the other has been developed from the bacterial virus called Q beta.One vaccine candidate has been developed from the plant virus named cowpea mosaic virus while the other has been developed from the bacterial virus called Q beta.

The Drugs Controller General of India (DCGI) on Friday granted permission to the Mukesh Ambani-owned Reliance Life Sciences to conduct phase-I clinical trial of its indigenous COVID-19 vaccine with certain conditions, sources said.

The phase-I clinical trial will be conducted to evaluate safety, tolerability and immunogenicity of the SARS-CoV-2 recombinant protein subunit vaccine in healthy volunteers according to protocol, they said.

The firm is required to submit the revised clinical trial protocol for immunogenicity to be assessed on Day 42, instead of Day 14, as recommended by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation, a source said, citing the conditions set for the trial.

The DCGI gave the permission based on the recommendations given by the SEC which deliberated on the company’s application on August 26.

The trials will be conducted at eight sites in Maharashtra.

India’s drug regulator has so far issued emergency use authorisation to six COVID-19 vaccines—Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV-D, Russian-made Sputnik V and the two made by US firms Moderna and Johnson & Johnson.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Key data on U.S. Johnson & Johnson, Moderna COVID-19 booster shots ‘weeks away,’ says Fauci
2Stringent lockdown where COVID-19 spread is critical, says Kerala govt
3Kerala records 19,653 fresh COVID-19 cases, 152 deaths